FDA approves new indication for Botox

SILVER SPRING, Md. — The Food and Drug Administration has approved a new indication for Allergan’s Botox (onabotulinumtoxinA). The drug can now be used to treat lower limb spasticity in adult patients as a way of decreasing the severity of muscles stiffness in ankle or toe muscles. 

 

The new indication comes just a few months after the FDA approved Botox to treat upper limb spasticity in two thumb muscles and six years after it was approved to treat upper limb spasticity in the elbow, wrist and fingers. 

 

“Spasticity is a debilitating condition that can have a significant impact on patients' lives, compromising their ability to perform a range of daily activities,” Botox SVP global development and scientific officer Dr. Mitchell Brin said. “This FDA approval marks our continued commitment to partnering with scientists and researchers around the world to explore the potential benefits of Botox in treating specific medical conditions. We are pleased that through this research, we are now able to offer this treatment option for patients with lower limb spasticity.”